

Molecular Cancer Therapeutics

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers

Sean P. Pitroda, Melinda E. Stack, Gene-Fu Liu, et al.

Mol Cancer Ther 2018;17:732-739. Published OnlineFirst February 21, 2018.

Updated version Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-17-0667](https://doi.org/10.1158/1535-7163.MCT-17-0667)

Supplementary Material Access the most recent supplemental material at:
<http://mct.aacrjournals.org/content/suppl/2018/02/21/1535-7163.MCT-17-0667.DC1>

Cited articles This article cites 46 articles, 12 of which you can access for free at:
<http://mct.aacrjournals.org/content/17/4/732.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/17/4/732>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.